Franklin Genomic Advancements ETF (BATS:HELX – Get Free Report) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 4,118 shares, a decrease of 74.2% from the June 30th total of 15,981 shares. Based on an average daily volume of 3,276 shares, the short-interest ratio is presently 1.3 days. Currently, 1.0% of the company’s stock are sold short.
Institutional Investors Weigh In On Franklin Genomic Advancements ETF
Several institutional investors have recently added to or reduced their stakes in HELX. Kestra Advisory Services LLC purchased a new stake in shares of Franklin Genomic Advancements ETF during the fourth quarter worth about $39,000. Raymond James Financial Inc. purchased a new position in shares of Franklin Genomic Advancements ETF in the 2nd quarter valued at approximately $42,000. Osaic Holdings Inc. raised its position in shares of Franklin Genomic Advancements ETF by 19.1% in the 2nd quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock valued at $87,000 after purchasing an additional 502 shares during the last quarter. Finally, LPL Financial LLC grew its position in Franklin Genomic Advancements ETF by 22.4% during the 4th quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after purchasing an additional 2,037 shares during the last quarter.
Franklin Genomic Advancements ETF Price Performance
Franklin Genomic Advancements ETF stock opened at $38.86 on Tuesday. Franklin Genomic Advancements ETF has a 1-year low of $27.54 and a 1-year high of $41.30. The business has a fifty day moving average price of $37.33 and a 200-day moving average price of $35.44. The stock has a market capitalization of $15.54 million, a price-to-earnings ratio of 26.71 and a beta of 1.05.
Franklin Genomic Advancements ETF Company Profile
The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.
Featured Stories
- Five stocks we like better than Franklin Genomic Advancements ETF
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Franklin Genomic Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Franklin Genomic Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
